EXACT Sciences Corporation Announces Final Payment Decision For Cologuard® From The Centers For Medicare & Medicaid Services

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS) today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final payment decision regarding Cologuard and will reimburse it at $502 per test. Cologuard is the first and only FDA-approved noninvasive stool DNA colorectal cancer screening test.

Help employers find you! Check out all the jobs and post your resume.

Back to news